Biopharmaceutical company Amarin Corporation (AMRN) reported better-than-expected Q2 results, which surpassed both earnings and revenue estimates on the back of higher revenues from increased volume of VASCEPA sales in the United States. The company reported earnings of $0.02 per share, up 50% from the year-ago period, surpassing the Street’s estimate of a loss of $0.03 per share. Additionally, revenue climbed 14% year-over-year to $154.5 million, beating analysts’ estimates of $153.8 million. Net product revenue surged 15% to $153.8 million during the quarter. (See Amarin stock charts on TipRanks) As of June 30, the company’s balance sheet remained strong with no debt holdings and $523.1 million in total cash and investments.
https://www.tipranks.com/news/amarin-q2-earnings-revenues-surpass-estimates?utm_source=advfn.com&utm_medium=referral
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Amarin Charts.
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Amarin Charts.